NASDAQ:VBLT Vascular Biogenics (VBLT) Stock Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free VBLT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.34▼$6.7450-Day Range$0.16▼$5.4652-Week Range$0.10▼$6.74Volume161,505 shsAverage Volume2.19 million shsMarket Capitalization$423.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vascular Biogenics alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Vascular Biogenics Stock (NASDAQ:VBLT)Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.Read More Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now VBLT Stock News HeadlinesNovember 3, 2023 | msn.comVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26October 16, 2023 | finance.yahoo.comNotable Labs Closes Merger Transaction With VBL TherapeuticsApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.October 12, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingSeptember 9, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 6, 2023 | finance.yahoo.comVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.August 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 23, 2023 | fool.comVascular Biogenics (NASDAQ: VBLT)May 15, 2023 | finance.yahoo.comVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 4, 2023 | benzinga.comVascular Biogenics Stock (NASDAQ:VBLT), DividendsMarch 17, 2023 | finance.yahoo.comVascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)March 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comVBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashFebruary 27, 2023 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLTFebruary 23, 2023 | technews.tmcnet.comVBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to ShareholdersFebruary 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. MergerFebruary 23, 2023 | marketwatch.comVascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLTFebruary 23, 2023 | msn.comVascular Biogenics rises 85% on all-stock merger deal with Notable LabsFebruary 23, 2023 | investorplace.comWhy Is Vascular Biogenics (VBLT) Stock Up 52%?February 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in CashNovember 10, 2022 | finance.yahoo.comOYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesSeptember 2, 2022 | finance.yahoo.comAxsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07September 1, 2022 | finance.yahoo.comVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySee More Headlines Receive VBLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webwww.vblrx.com Phone(728) 993-5000Fax972-8993-5001Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,300,000.00 Net MarginsN/A Pretax Margin-3,317.05% Return on Equity-73.45% Return on Assets-54.11% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.63 Sales & Book Value Annual Sales$660,000.00 Price / Sales642.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book17.06Miscellaneous Outstanding Shares77,640,000Free Float72,881,000Market Cap$423.91 million OptionableOptionable Beta0.77 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesProf. Dror Harats M.D. (Age 66)CEO & Director Comp: $444.33kMr. Samuel Backenroth (Age 39)Chief Financial Officer Comp: $410kDr. Eyal Breitbart Ph.D. (Age 56)Sr. VP of Research & Operations Advocate Ayelet Horn (Age 52)Gen. Counsel Dr. Erez Feige M.B.A. (Age 49)Ph.D., Sr. VP of Bus. Operations Key CompetitorsAvid BioservicesNASDAQ:CDMOLexicon PharmaceuticalsNASDAQ:LXRXEntrada TherapeuticsNASDAQ:TRDALarimar TherapeuticsNASDAQ:LRMRADC TherapeuticsNYSE:ADCTView All Competitors VBLT Stock Analysis - Frequently Asked Questions How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company earned $0.20 million during the quarter, compared to analyst estimates of $0.20 million. During the same period in the previous year, the company earned ($0.12) earnings per share. What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN). This page (NASDAQ:VBLT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.